KeyPRP — High-Dose, Customizable Platelet-Rich Plasma

High-dose platelet-rich plasma refers to PRP preparations engineered to deliver clinically meaningful platelet quantities — typically at or above the 10 billion platelet benchmark identified in recent peer-reviewed literature as associated with more consistent outcomes. Single-spin and low-volume systems often deliver only 1–3 billion platelets per dose. High-dose systems use validated dual-spin protocols and optimized collection geometry to recover and concentrate platelets up to 30x over baseline whole-blood concentration.

Sources

• Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci Rep. 2021;11(1):3971.
• Single-spin platelet quantity range and 30x concentration figure: industry-general / Cervos Data on File.

Recent clinical research has identified approximately 10 billion platelets as a threshold above which PRP studies have shown more consistent improvement in pain and function scores. Doses below ~5.5 billion platelets have shown inconsistent results across published studies, while doses meeting or exceeding the 10 billion benchmark have demonstrated sustained outcomes at one-year follow-up in the literature. The KeyPRP™ system is engineered to consistently deliver platelet quantities in this range.

Sources

• Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci Rep. 2021;11(1):3971.
• Patel S, Gahlaut S, Thami T, Chouhan DK, Jain A, Dhillon MS. Comparison of conventional dose versus superdose platelet-rich plasma for knee osteoarthritis: a prospective, triple-blind, randomized clinical trial. Orthop J Sports Med. 2024;12(2):23259671241227863.
• Everts PA, Lana JF, Onishi K, et al. Angiogenesis and tissue repair depend on platelet dosing and bioformulation strategies following orthobiological platelet-rich plasma procedures: a narrative review. Biomedicines. 2023;11(7):1922.

The difference is composition. Leukocyte-poor PRP minimizes white blood cells — particularly granulocytes — resulting in leukocyte content typically below baseline whole-blood levels. Leukocyte-rich PRP retains a higher concentration of leukocytes, generally several times above baseline. The choice between leukocyte-poor and leukocyte-rich preparation is made by the treating physician based on the patient and the specific procedure or application. KeyPRP™ allows either preparation from a single closed system.

Sources

• DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012;28(7):998–1009.
• Mautner K, Malanga GA, Smith J, et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM&R. 2015;7(4 Suppl):S53–S59.

Double-spin PRP systems generally yield significantly higher platelet concentrations than single-spin systems. Single-spin protocols are faster but typically deliver concentrations of 2–5x over baseline. Double-spin protocols, like the AABB-aligned process used in KeyPRP™, recover more platelets and allow volume reduction down to 1.5 cc, achieving concentrations up to 30x over baseline. The trade-off is a slightly longer preparation step.

Sources

• Magalon J, Bausset O, Serratrice N, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30(5):629–638.
• 30x concentration and 1.5 cc minimum volume figures: KeyPRP Data on File.

Platelet-rich plasma has been studied across a range of orthobiologic and aesthetic applications. In orthopedic and sports medicine, peer-reviewed research includes studies in knee osteoarthritis, tendinopathies, and soft-tissue applications. In aesthetics and dermatology, PRP has been studied in hair restoration and facial protocols. Decisions about clinical use are made by the treating physician based on the patient, the procedure, and the published evidence relevant to the specific application.

Sources

• Belk JW, Kraeutler MJ, Houck DA, et al. Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Am J Sports Med. 2021;49(1):249–260.
• Filardo G, Di Matteo B, Kon E, Merli G, Marcacci M. Platelet-rich plasma in tendon-related disorders: results and indications. Knee Surg Sports Traumatol Arthrosc. 2018;26(7):1984–1999.
• Gupta AK, Carviel J. A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia. Dermatol Surg. 2016;42(12):1335–1339.